1 

OniX Competitive Analysis Agent

Example Case Studies →

One search, one report, across 20 real sources spanning research funding, publications, and clinical trials — global grants (US, UK, EU, France, Australia, Japan, the Netherlands), what's actually been published (including preprints not yet peer reviewed), and what's in clinical development right now, plus a live news feed. See Page 3 for the full source-by-source list.​

​

One search produces different reports depending on how you search — by topic, or by PI/institution/foundation — each answering a different question that matters to you:

​

Foundation & TTO Reports

Use the "Search by PI, Institution, or Foundation" panel instead of Topic/Context.

​

1. PI Grants, Publications & Clinical Trials — "What has this researcher (or list of researchers) actually done?" Who it's for: TTOs triaging disclosures, department administrators reviewing their own faculty, foundations checking a grantee. What you get: every grant, publication, and clinical trial tied to one PI, or rolled up across an uploaded list — each scored on the new OniX Innovation Scale.

​

2. PI Group Overview — "Which of these researchers deserve a closer look?" Who it's for: anyone triaging a larger uploaded list (5-20 names) at a glance rather than reading each one individually. What you get: a rollup view plus a per-PI table, signal-scored, so the highest-priority names surface first.

​

3. PI Partnership Snapshot — "Is it the right time to approach this PI or researcher?" Who it's for: anyone doing a fast first read on a researcher before reaching out — BD, TTOs, foundations. What you get: a condensed working profile, not the full record dump — built for a quick yes/no, not exhaustive review.

​

4. Funder Acknowledgment — "What has this funding actually produced?" Who it's for: Program Officers and foundation Development/ Communications teams, as well as industry funders (pharma, biotech) tracking their own grant-funded research. What you get: publications and trials that structurally credit a specific funder's support — pulled from each publication's own funder metadata, not a text guess.

​

5. Foundation Grant Portfolio (coming soon) A foundation's entire grant portfolio viewed as one whole — every grant it's made, not just what one grantee has published.

​

6. Institution Invention-Readiness Scan — "How much of this institution's output looks patent-worthy?" Who it's for: TTOs prioritizing where to look first across many researchers, before committing to a full disclosure review. What you get: institution-wide output ranked by the OniX Innovation Scale's own novelty signal (first-in-class/breakthrough language, semantic novelty detection) — a prioritization signal built from App1's own literature and grant analysis, not a patent database search. Pair with App4's actual patent landscape once you know where to look first.

​

7. Org-Wide Funding & Publications Profile — "What has this whole organization produced?" Who it's for: TTOs, foundations, and BD teams sizing up an institution or company as a whole. What you get: every grant, publication, and clinical trial tied to that organization — the entity-level counterpart to the topic-level Comprehensive Research & Funding report.

​

8. Overlap/Duplicate Funding Audit (coming soon) Checks whether a researcher's grants overlap in scope with other funding they already hold — flags potential duplicate funding before it becomes a compliance problem for a sponsored-projects office, or a due-diligence question for a funder.

​

9. Organization News Monitor — "What's the real, relevant press about this organization?" Who it's for: Foundations, TTOs, and institutions monitoring their own public profile — or researching a prospect, partner, or grantee's. What you get: a relevance-ranked news feed for an organization — real research/funding/philanthropy coverage promoted over hiring ads and unrelated mentions.

​

10. Who's Funding This Investigator (coming soon) The reverse of Funder Acknowledgment — shows which funders are acknowledged across a specific investigator's body of work, instead of what one funder's money produced.

​

11. Co-Funding Pattern (coming soon) Shows which funders commonly get acknowledged together on the same papers — useful for spotting co-funding relationships and potential partners.

​

12. Portfolio Gap (coming soon) A cross-portfolio rollup showing where the white space is across a foundation's or institution's funded research.

​

Research & Competitive Intelligence Reports

Use the Topic/Context panel above (only available in Search by Topic mode).

​

1. Comprehensive Research & Funding (CRF) — "What's out there in this space?" Who it's for: anyone who wants the complete picture on a research topic. What you get: every matching grant, publication, and clinical trial found, each with an AI-generated plain-English summary, mechanism of action, development stage, and therapeutic potential pulled straight from the abstract. Real, not guessed, for ClinicalTrials.gov's own Asset/Stage fields — every other source's snapshot is AI-inferred and clearly labeled as such.

​

2. CRF Executive Brief — "What are the key findings, fast?" Who it's for: anyone who needs the CRF's headline findings without reading every underlying record. What you get: the same topic report as Comprehensive Research & Funding, shortened to the key findings with a table of contents.

​

3. Executive One-Pager — "Is this space worth a closer look?" Who it's for: anyone who needs a go/no-go read on a space in under a minute. What you get: a one-page screening view — record counts, a modality breakdown, a crowded-vs-white-space read on each modality, and the most active organizations.

​

4. Partnering Researcher Landscape — "Who's currently active, and who should we talk to?" Who it's for: anyone starting a partnering or licensing conversation who needs the right names first. What you get: ranks the people and organizations actually working in a space right now — grants first, publications second — each linking straight back to its real grant or paper.

​

5. Emerging Innovation — "What's actually novel here, not just active?" Who it's for: anyone trying to spot the standout signals in a large pile of research rather than reading everything. What you get: scans every record for concrete novelty language ("first-in-human," "novel," "breakthrough," "first-in-class") rather than just surfacing whoever is best-funded, with an adjacent-opportunity comparison showing related areas worth a look.

​

6. Target Validation & Opportunity — "What's the full genetic-target picture for this space?" Who it's for: pharma/biotech teams deciding whether a target is worth pursuing. What you get: the complete Open Targets disease-association picture for a topic — every disease association returned, known drugs/clinical candidates already in that space, and the same adjacent-opportunity comparison as Emerging Innovation. Only produced when the topic resolves to a real Open Targets target.

​

7. Funding Signal — "Who is actively funding work on my topic, and by whom?" Who it's for: anyone scanning a topic for active funders — BD, foundations, researchers scoping where the money is right now. What you get: every funder actively supporting work on a topic, pulled from 10 live government grant portals (NIH, NSF, UKRI, USASpending, ARC, CORDIS, NWO, ANR, JSPS, NHMRC) plus foundation funding records and publications' own funder-acknowledgment text — grouped by funder and tagged Government, Foundation, Industry, or Uncategorized.

​

8. Funding Signal — Publications — "Who has been formally acknowledged as funding published research on this topic, historically?" Who it's for: anyone who wants funding history sourced from what's actually been published, including funders that never show up in a grants-database search. What you get: funders drawn directly from each publication's own resolved funder-acknowledgment data — catches foundations and companies invisible to a grant-portal-only search.

​

9. Clinical Trial Site Experience — "Which sites have real, relevant experience running trials for this condition?" Who it's for: sponsors and CROs choosing trial sites. What you get: which hospitals/universities have actually run trials for a condition, each site paired with the specific condition studied there and a cohort snapshot (age bracket, sex) pulled from that trial's own eligibility criteria.

​

10. CT Protocol Benchmark & Design — "How does a draft protocol compare to the field, before it's locked?" (In Development — see note at bottom) Who it's for: anyone finalizing a trial design before submission. What you get: eligibility criteria and endpoints benchmarked against existing trials for a condition, with a Trial Complexity Score, comparison tables and chart images, a Phase Progression table by intervention, and a composite "typical eligibility profile + endpoint set" view — catches an over-strict or off-standard design early.

​

11. Preclinical Methods (In-Vitro/In-Vivo) (In Development) Who it's for: startups/biotechs planning early-stage work who want a free first-pass read of what's already been published. What you get: in-vitro/in-vivo methods used in published literature for a target, and which of those programs reached clinical Phase 1+.

​

12. FDA Preclinical Package Digest (coming soon) Who it's for: startups/biotechs who want a real teaching precedent. What you get: for an approved drug, a digest of the actual nonclinical studies FDA's own reviewers saw in that drug's NDA/BLA approval package (species/strain, group sizes, doses, route, duration, endpoints) — sourced from the regulatory record itself, not mined literature.

​

13. NIH Grant Trends (coming soon) Who it's for: anyone deciding whether a space is worth entering or has already peaked. What you get: category-level, year-over-year NIH funding trends for a topic.

​

14. Funding Match & Targeting (coming soon) Who it's for: researchers and grants staff preparing a new submission. What you get: which NIH Institute/Center and which funding mechanism (R01, R21, U01, SBIR/STTR, and others) actually fund work in this space.

​

Bonus context in every report, regardless of scope: open Grants.gov opportunities, the OniX OnPoint newsletter, and hyperlinked Google News headlines.

Recurring monitoring, not just a one-time report: save up to 5 searches and schedule them daily, weekly, or monthly — the Agent checks in the background (even with the app closed) and drops a finished report in your folder with a Mac notification when it's done.

Example use case: A TTO evaluating whether to file on a new compound runs the Agent before committing legal spend — one report shows who else is funded to work on it, what's been published, and whether it's already in trials, in about the time it takes to get coffee.

2

OniX Patent Agent

Example Case Studies →

Worldwide patent search across roughly 100 patent offices, plus a dedicated US-only mode, with the Data Source picked right in the app window. Espacenet/EPO OPS is the worldwide source; USPTO's own Open Data Portal is the US-only source — each needs its own free API key(s), tied to your account and your own request quota (see Setup & Instructions).

What's in the reports:

• Landscape Overview — "Who else is working in this space, and how crowded is it?" Who it's for: academic TTOs scoping a technology area, biotech teams sizing up competitors, VCs doing a first pass on a space. What you get: relevance-ranked results with real abstracts and AI summaries, top applicants, technology clusters, jurisdictions, filing trends over time, and an asset-type breakdown.

​

• Compare My Asset — "How does MY invention compare to what's already out there, and what's my real risk?" Who it's for: inventors and founders deciding whether to file, TTOs weighing patent-vs-license, VCs running quick diligence on a target's novelty. What you get: your invention description compared directly against retrieved prior art's real abstract text — the closest matches, what elements they share, how yours differs. No guessed percentage, no black-box score — every claim traces to a real passage of text. Paste your description or attach a draft (.txt/.docx/.pdf).

​

• Novelty & Prosecution Risk — "Where does prior art hit hardest, and who's had the roughest path to grant?" Who it's for: portfolio strategists, diligence teams gauging how hard-won a target's IP really is. What you get: real citation-severity data pulled from each EP application's own examiner search report (the official X/Y/A relevance codes patent offices already assign), rolled up by technology cluster and applicant, plus opposition status.

​

Example use case: Before further investment, a patent attorney or BD lead gets a first-pass read on whether an asset's chemical space is crowded or wide open, across US and international filings, before commissioning a formal freedom-to-operate opinion.

3

OniX Regulatory Agent

Example Case Studies →

Regulatory feedback and pathway analysis for a specific asset — grounded in real FDA and CMS data, not a legal opinion. Built as a guided, chat-style intake: describe your asset in your own words (or attach up to 3 files for it to read), and the Agent asks follow-up questions only where it isn't confident, then shows you the exact search terms it's about to use before anything runs.

What's in the report: 

• Academic/TTO Asset Pre-Screen (the baseline) Who it's for: TTOs and academic researchers screening a molecule before pursuing IP protection or licensing; startups doing an early sanity check. What's inside: FDA approvals, safety signals and labeling, Orphan Drug Designation, CMS reimbursement benchmark, special-modality flags (DEA/NRC/USDA-APHIS — animal-health and veterinary questions included, not just human drugs), stage-appropriate oversight guidance, related clinical trials, and recent news.

​

• Product Development Plan & Investor Deck (beta add-on) Who it's for: founders and TTOs prepping for investor conversations. What's inside: a draft Product Development Plan (Word) and a draft Investor Deck (PowerPoint), built from the same run's findings.

​

• Asset Valuation & FTO Report — "What is this asset worth, and how much runway and protection does it have?" Who it's for: VCs doing deal diligence, TTOs valuing a license, startups building a fundraising case. What's inside: Orphan Exclusivity Runway (estimated years of remaining market exclusivity), Clinical-to-Approval Velocity (how fast comparable assets have historically moved from trial to approval), and Cross-Agency Regulatory Moat (extra DEA/NRC/USDA-EPA requirements that raise the bar for fast-followers).

​

• Competitive Intelligence & Pipeline Disruption Dashboard — "Who else is coming after this space?" Who it's for: BD/corp dev teams at pharma and biotech, VCs monitoring a portfolio company's competitive position. What's inside: a Pre-Approval Competitive Threat Matrix — active related trials, orphan drug designations, and a class-crowding signal in one view.

​

• De-Risking & IND-Enabling Due Diligence Report — "What could slow or derail this asset, and what hidden costs come with it?" Who it's for: VCs and biotechs prepping for an IND, TTOs building licensing packages, pharma BD doing early diligence. What's inside: a Specialized Overhead Risk Flag — DEA/NRC/USDA-EPA co-regulation that adds real cost and timeline risk beyond standard FDA requirements.

​

Example use case: An animal-health innovation team checks a repurposed compound's regulatory footprint before committing to an indication — the FDA-CVM and USDA-APHIS flags surface obligations a human-drug-only search would miss entirely.

4

OniX Asset Intelligence Agent - Consultation only

A single private due-diligence report on a specific asset — small molecule, peptide, or natural product — built entirely on your own machine, run by our team on your request. Describe one asset once; every report below draws on the same Target & Structure data already gathered (Human Protein Atlas, PubChem, ChEMBL, PubMed, RDKit).

• Full Due-Diligence Report (always runs — the baseline) Who it's for: anyone doing first-pass diligence on an asset — biotech teams, TTOs, VCs, pharma BD. What's inside: five sections (Target & Structure, Competitive Landscape, Regulatory Signal, Patent Landscape, Product Development Plan) plus an optional draft investor deck.

• Structural Pivot & Fast-Follower Report — "Where's the easiest design-around path for a competitor, and does it lead somewhere worse?" Who it's for: TTOs and patent committees deciding what to file; startups building a defensive filing strategy; VCs assessing IP moat durability. What's inside: this asset's closest structural analogs grouped by the kind of change involved, each group ranked by how many analogs already exist in that direction — with real ChEMBL safety flags shown alongside sourced analogs, never estimated where the data doesn't exist.

• Safety Window Flag Report — "Does this target's tissue expression suggest an off-target toxicity risk?" Who it's for: biotech teams and VCs doing early safety triage before IND-enabling studies; TTOs screening for red flags before filing. What's inside: tissue-expression profile (Human Protein Atlas) alongside bioactivity/potency data (ChEMBL) — a qualitative flag, deliberately never a fake-precise numeric "safety margin."

Let us run it for you — Call for a Quote.

Example use case: Before licensing in an asset, a biotech's BD team gets one report that answers "does this look novel, is anyone ahead of us, what's the regulatory path, and is the patent space crowded" — instead of commissioning four separate studies.